Targeted Approach for Prevention and Therapy of Colorectal Cancer
Targeted Approach for Prevention and Therapy of Colorectal Cancer
批准号:
9046378
负责人:
Vincent W Yang
金额:
$34.17万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2018-04-30
关键词:
Antineoplastic AgentsApcMin/+ miceApoptosisBioavailableCancer EtiologyCancer cell lineCell CycleCell ProliferationCessation of lifeColon CarcinomaColorectal CancerDataDevelopmentDiseaseDrug CompoundingDrug KineticsEpithelialEpithelial Cell ProliferationEpithelial CellsGerm-Line MutationGoalsHealthHumanImpairmentIn VitroIntestinal NeoplasmsIntestinesKRAS2 geneKnowledgeLeadLifeLinkMediatingModificationMolecularMorbidity - disease rateMusMutationNeoplasm MetastasisOncogenicPathway interactionsPatternPhosphotransferasesPlayPreventionPrevention therapyPropertyResearch ProposalsRoleSignal PathwayStructureStructure-Activity RelationshipTestingTherapeuticTherapeutic AgentsTherapeutic UsesTissuesTransgenic MiceTumor Suppressor GenesUnited StatesUp-RegulationXenograft Modelanalogbasecancer cellcancer therapycellular targetingcolon cancer cell linecolon carcinogenesiscrypt celldrug metabolismimprovedin vivoinhibitor/antagonistintestinal cryptmigrationmortalitymouse modelnovelnovel therapeuticsoverexpressionphysical propertypreclinical efficacypreventresearch studyscaffoldscreeningsmall moleculetumorigenesis
中文摘要
描述(由申请人提供):结直肠癌(CRC)是美国癌症发病率和死亡率的主要原因之一。从正常肠上皮组织到转移性肿瘤的多步骤进展是由于多种调节机制的损害,包括调节正常增殖、分化、迁移和凋亡模式的关键信号通路。其中,Wnt和RAS信号通路在控制肠细胞增殖中起着至关重要的作用,也是最常受到干扰的
英文摘要
DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is one of the leading causes of cancer morbidity and mortality in the United States. The multistep progression from normal intestinal epithelial tissue to metastatic neoplasm results from impairment of multiple regulatory mechanisms involving critical signaling pathways that regulate normal patterns of proliferation, differentiation, migration, and apoptosis. Among these, the Wnt and RAS signaling pathways play crucial roles in governing intestinal cell proliferation and are the most frequently perturbed
in colorectal cancer. Despite this knowledge, few therapeutic strategies have been developed to specifically target components of these particular pathways, and none have gained FDA approval. Our group has identified Kr¿ppel-like factor 5 (KLF5) as an important regulator of intestinal epithelial cell proliferation that is frequently overexpressed during intestinal tumorigenesis. Recently, we have linked KLF5 to both the RAS and Wnt signaling pathways in colorectal carcinogenesis. Our group has also observed that reduction in KLF5 expression leads to reduced intestinal tumor formation in mice harboring a germline mutation in the tumor suppressor gene, APC, a crucial component of the Wnt pathway, or combined APC and KRAS mutations. Using an ultrahigh-throughput screening (uHTS) approach to identify novel lead compounds with potential therapeutic benefits by targeting KLF5 expression, followed by structure-activity studies on the resultant hits, we identified a novel small molecule, ML264, which potently and selectively blocks KLF5 expression in and decreases proliferation of colorectal cancer cell lines. We propose to further characterize the mechanisms by which ML264 inhibits KLF5 expression and evaluate its efficacy as a therapeutic agent for colorectal cancer. The Long-Term Goal of this research proposal is to develop and characterize novel therapeutic agents for the prevention and/or treatment of colorectal cancer. Based on our results we propose the Central Hypothesis that the compound ML264 prevents colorectal cancer development and progression by decreasing KLF5 expression in vivo. To test this hypothesis we propose three Specific Aims: 1) To investigate the mechanism by which ML264 regulates KLF5 expression in CRC cells; 2) To evaluate the preclinical efficacy of compound ML264 in preventing colon cancer formation in mouse models of colorectal cancer; and 3) To generate optimized analogs of ML264 with fully appropriate pharmacokinetic properties for anticancer therapy. The experiments proposed in this application will provide a definitive refinement of the structure and function of ML264 and its optimized analogs. The intent of this effort is to obtain well-tolerated, long-lived bioavailable compounds suitable for therapeutic use in colorectal cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted Approach for Prevention and Therapy of Colorectal Cancer
-
批准号:8688968
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2013
-
负责人:Vincent W Yang
-
依托单位:
Targeted Approach for Prevention and Therapy of Colorectal Cancer
-
批准号:8576271
-
项目类别:
-
资助金额:$37.17万
-
财政年份:2013
-
负责人:Vincent W Yang
-
依托单位:
Targeted Approach for Prevention and Therapy of Colorectal Cancer
-
批准号:9272387
-
项目类别:
-
资助金额:$34.17万
-
财政年份:2013
-
负责人:Vincent W Yang
-
依托单位:
Molecular Mechanisms Regulating Intestinal Homeostasis
-
批准号:8434533
-
项目类别:
-
资助金额:$34.15万
-
财政年份:2012
-
负责人:Vincent W Yang
-
依托单位:
Molecular Mechanisms Regulating Intestinal Homeostasis
-
批准号:8694017
-
项目类别:
-
资助金额:$34.37万
-
财政年份:2012
-
负责人:Vincent W Yang
-
依托单位:
Molecular Mechanisms Regulating Intestinal Homeostasis
-
批准号:8542833
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2012
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Center
-
批准号:8011156
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2010
-
负责人:Vincent W Yang
-
依托单位:
Biology and Pathobiology of Kr??ppel-Like Factors (KLFs)
-
批准号:8004659
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2010
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Center
-
批准号:7868610
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2009
-
负责人:Vincent W Yang
-
依托单位:
Regulation of Intestinal Epithelial Cell Proliferation
-
批准号:7898182
-
项目类别:
-
资助金额:$7.93万
-
财政年份:2009
-
负责人:Vincent W Yang
-
依托单位:
High Throughput Screen for Small Molecule Inhibitors of Colorectal Cancer Cell Pr
-
批准号:7522200
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2008
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development
-
批准号:6618543
-
项目类别:
-
资助金额:$51.86万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Center
-
批准号:7869291
-
项目类别:
-
资助金额:$54.25万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Center
-
批准号:7390027
-
项目类别:
-
资助金额:$50.33万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Cent*
-
批准号:6897789
-
项目类别:
-
资助金额:$51.86万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Center
-
批准号:7238477
-
项目类别:
-
资助金额:$49.17万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Cent*
-
批准号:6765326
-
项目类别:
-
资助金额:$51.86万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
Emory Epithelial Pathobiology Research Development Cent*
-
批准号:7068112
-
项目类别:
-
资助金额:$50.64万
-
财政年份:2003
-
负责人:Vincent W Yang
-
依托单位:
DIFFERENTIAL GENE EXPRESSION IN INTESTINAL CELL LINES
-
批准号:6500423
-
项目类别:
-
资助金额:$10.37万
-
财政年份:2001
-
负责人:Vincent W Yang
-
依托单位:
Molecular Medicine of Colorectal Cancer
-
批准号:6335556
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2001
-
负责人:Vincent W Yang
-
依托单位:
海外基金